<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411905</url>
  </required_header>
  <id_info>
    <org_study_id>GFM BAR-C-2005</org_study_id>
    <nct_id>NCT00411905</nct_id>
  </id_info>
  <brief_title>Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes</brief_title>
  <official_title>Phase I/II Study of Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are evaluating the efficacy of the association of Low dose Cytarabine in association with
      Bortezomib in the treatment of patients diagnosed with high risk Myelodysplastic syndromes.
      Our aim is to decrease transfusion requirements and if possible induce a complete or at least
      a partial remission.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Four cycles of treatment are proposed at 28 day intervals in an ambulatory setting

      Cycle 1 :

        -  Cytarabine 10 mg /m2/day subcutaneous injection for 14 days

        -  Bortézomib 1,5mg/m2 days 1,4,8,11

      Cycles 2, 3, 4 :

        -  Cytarabine 20 mg /m2/j subcutaneous injections for 14 days

        -  Bortézomib 1,5mg/m2 days 1,4,8,11

      Bone marrow aspirates are evaluated just before the first cycle, after the second and after
      the fourth cycles

      Responding patients may continue the treatment for 2 further cycles
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2006</start_date>
  <completion_date>June 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Partial Response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematological Improvement</measure>
  </secondary_outcome>
  <enrollment>39</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MDS with IPSS scores Int-2 or High

          -  Life expectancy greater than 6 months

          -  No other available treatment options

        Exclusion Criteria:

          -  MDS with IPSS scores Low or Int-1

          -  &gt; 30% bone marrow blasts

          -  clinical neuropathy of greater than grade 2

          -  ECOG Score 3 or 4

          -  Creatinine clearance of &lt; 30 ml/min

          -  LMMC

          -  Pregnant patients or lactating mothers

          -  Patients having received intensive chemotherapy in the 3 months prior to inclusion

          -  Patients with uncontrolled pulmonary, cardiac, neurological, gastro-intestinal or
             genito-urinary disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois DREYFUS, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe francaise des Myelodysplasies</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shanti Natarajan-Amé, MD</last_name>
    <phone>00 33 3 88 12 76 70</phone>
    <email>shanti.ame@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marjorie Sidhoum, CRA</last_name>
    <phone>00 33 3 88 12 81 48</phone>
    <email>marjorie.sidhoum@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>43033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathilde HUNAULT-BERGER, Professor</last_name>
      <phone>00 33 241354475</phone>
      <email>MaHunault@chu-angers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Martine Gardembas-Pain, MD</last_name>
      <phone>00 33 241354705</phone>
      <email>MaGardembas@chu-angers.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Mathilde HUNAULT-BERGER, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre FENAUX, MD</last_name>
      <phone>00 33 1 48 95 70 50</phone>
      <email>pierre.fenaux@avc.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Fatima Hamza, CRA</last_name>
      <phone>00 33 1 48 95 58 90</phone>
      <email>fatima.hamza@avc.aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre FENAUX, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josy REIFFERS, Profesor</last_name>
      <phone>00 33 05 56 33 33 00</phone>
      <email>reiffers@bergonie.org</email>
    </contact>
    <contact_backup>
      <last_name>Gabriel ETIENNE, MD</last_name>
      <phone>00 33 5 56 33 44 19</phone>
      <email>gabriel.etienne@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Josy Reiffers, Profesor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel ETIENNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane CHEZE, MD</last_name>
      <phone>00 33 2 31 27 23 60</phone>
      <email>cheze-s@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane CHEZE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth BERGER, MD</last_name>
      <phone>00 33 3 80 29 50 41</phone>
      <email>elisabeth.berger@chu-dijon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Monique Grandjean, CRE</last_name>
      <phone>00 33 80 29 50 47</phone>
      <email>monique.grandjean@chu-dijon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Eric SOLARY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth BERGER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves CAHN, Professor</last_name>
      <phone>00 33 4 76 76 94 45</phone>
      <email>JYCahn@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stephane COURBY, MD</last_name>
      <phone>00 33 4 76 76 59 53</phone>
      <email>Scourby@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Yves CAHN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique BORDESSOULE, Profesor</last_name>
      <phone>00 33 5 55 05 66 42</phone>
      <email>bordessoule@unilim.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique BORDESSOULE, Profesor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert VEY, MD</last_name>
      <phone>00 33 4 31 22 36 95</phone>
      <email>veyn@marseille.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Norbert VEY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aude CHARBONNIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reda BOUABDALLAH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence LEGROS, DOCTOR</last_name>
      <phone>00 33 4 92 03 58 44</phone>
      <email>legros@nice.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence LEGROS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FRANCOIS DREYFUS, Profesor</last_name>
      <phone>00 33 1 58 41 21 20</phone>
      <email>francois.dreyfus@ch.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie Klein, CRE</last_name>
      <phone>00 33 1 58 41 20 44</phone>
      <email>nathalie.klein@cch.aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>François DREYFUS, Profesor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Joffre</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence Sanhes, MD</last_name>
      <phone>00 33 468616448</phone>
      <email>laurence.sanhes@ch-perpignan.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence Sanhes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henry Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de STRASBOURG</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanti NATARAJAN-AME, MD</last_name>
      <phone>00 33 3 88 12 76 70</phone>
      <email>shanti.ame@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marjorie SIDHOUM, CRA</last_name>
      <phone>00 33 3 88 12 81 48</phone>
      <email>marjorie.sidhoum@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Shanti NATARAJAN-AME, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guy Laurent, MD</last_name>
      <phone>00 33 5 61 77 20 78</phone>
      <email>beynerauzy.o@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Guy LAURENT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Odile BEYNE-RAUZY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnes GUERCI-BRESLER, MD</last_name>
      <phone>00 33 3 83 15 3281</phone>
      <email>a.guerci@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Agnes GUERCI-BRESLER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2006</study_first_submitted>
  <study_first_submitted_qc>December 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2006</study_first_posted>
  <last_update_submitted>March 9, 2007</last_update_submitted>
  <last_update_submitted_qc>March 9, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2007</last_update_posted>
  <keyword>Myelodysplastic syndromes</keyword>
  <keyword>IPSS Int-2 and High risk</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Low dose Cytarabine</keyword>
  <keyword>Bone Marrow diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

